Lakefront Biotherapeutics Reports Q3 Revenue of €26.1M and GAAP EPS of €0.20
Lakefront Biotherapeutics (NASDAQ: LKFT) has released its financial results for the nine-month period, reporting a GAAP earnings per share (EPS) of €0.20. Despite maintaining profitability on an EPS basis, the company experienced a significant decline in top-line performance. Total revenue for the period reached €26.1 million, representing a sharp year-over-year decrease of 87.7%. This substantial drop in revenue suggests a major shift in the company's commercial activity or product lifecycle compared to the previous year.